Humacyte FY2029 Earnings Forecast Decreased by HC Wainwright

Key Points

• HC Wainwright cut Humacyte’s FY2029 EPS forecast to $0.07 from $0.09, while maintaining a Buy rating; it forecasts FY2030 EPS of $0.29.
• Humacyte’s latest quarterly results missed expectations: EPS was a loss of $0.16 versus a projected loss of $0.11, and revenue was $0.41 million versus $1.04 million expected.
• Analyst views remain mixed, though MarketBeat reports a consensus “Moderate Buy” rating and a $4.98 average price target.

Humacyte, Inc. (NASDAQ:HUMA - Free Report) - Stock analysts at HC Wainwright lowered their FY2029 earnings estimates for Humacyte in a report issued on Wednesday, November 11th. HC Wainwright analyst S. Ramakanth now anticipates that the company will post earnings per share of $0.07 for the year, down from their prior forecast of $0.09. HC Wainwright currently has a "Buy" rating on the stock. The consensus estimate for Humacyte's current full-year earnings is ($0.40) per share. HC Wainwright also issued estimates for Humacyte's FY2030 earnings at $0.29 EPS.

Humacyte (NASDAQ:HUMA - Get Free Report) last posted its earnings results on Wednesday, August 12th. The company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.05). Humacyte had a negative return on equity of 640.19% and a negative net margin of 3,955.05%. The business had revenue of $0.41 million for the quarter, compared to the consensus estimate of $1.04 million.

Other analysts have also issued reports about the company. Wall Street Zen lowered Humacyte from a "sell" rating to a "strong sell" rating in a report on Saturday, August 15th. Benchmark dropped their target price on Humacyte from $2.00 to $1.00 and set a "speculative buy" rating on the stock in a report on Thursday, August 13th. BTIG Research restated a "buy" rating and issued a $2.00 target price on shares of Humacyte in a report on Tuesday. Williams Trading set a $1.00 target price on Humacyte in a research report on Friday, October 16th. Finally, Weiss Ratings reiterated a "sell (e+)" rating on shares of Humacyte in a report on Friday, October 2nd. Six equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Humacyte currently has a consensus rating of "Moderate Buy" and a consensus target price of $4.98.

Humacyte Price Performance

Shares of NASDAQ HUMA opened at $0.59 on Thursday. Humacyte has a fifty-two week low of $0.34 and a fifty-two week high of $1.52. The stock has a market cap of $164.37 million, a price-to-earnings ratio of -1.34 and a beta of 2.64. The company has a debt-to-equity ratio of 2.07, a quick ratio of 5.74 and a current ratio of 6.21. The firm's 50-day simple moving average is $0.49 and its 200 day simple moving average is $0.78.

Hedge Funds Weigh In On Humacyte

Several hedge funds have recently modified their holdings of HUMA. Alyeska Investment Group L.P. bought a new position in shares of Humacyte in the second quarter valued at approximately $4,700,000. BlackRock Inc. bought a new stake in Humacyte during the second quarter worth $3,777,000. GSA Capital Partners LLP bought a new stake in Humacyte during the second quarter worth $785,000. Private Advisor Group LLC purchased a new position in Humacyte in the third quarter worth $491,000. Finally, State Street Corp boosted its position in Humacyte by 6.9% in the third quarter. State Street Corp now owns 900,646 shares of the company's stock worth $466,000 after purchasing an additional 58,109 shares during the last quarter. Institutional investors own 44.71% of the company's stock.

Humacyte Company Profile

Humacyte, Inc. is a biotechnology company developing bioengineered human tissues for use in regenerative medicine and vascular repair. The company's platform is designed to create implantable, off-the-shelf tissues that can be stored and used when needed without requiring the collection of tissue from the patient. Its primary product is SYMVESS, an acellular tissue-engineered vessel intended to replace or repair damaged blood vessels. In December 2024, the U.S. Food and Drug Administration approved SYMVESS for use in the urgent treatment of extremity arterial injuries when emergency vascular reconstruction is required.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.